Intravenous Immunoglobulin market Size to Cross US $16,882.15 Mn by 2026

June 21, 2019


Worldwide intravenous immunoglobulin market size is expected to exceed $16,882.15 million by 2026, according to the latest research available at Market Study Report LLC, report provides extensively data on market share, growth, trends and forecasts for the period 2018-2026.
 

For the uninitiated, immunoglobulins (IGs) are glycoproteins produced by blood plasma in response to the antigens (Ag), which are foreign materials to the host system. IGs are highly complex objects and precise in nature. They are produced from the blood through the fractionation process and filtered for therapeutic and non-therapeutic applications. In therapeutics, they are injected intravenously for treating various immunodeficiencies.
 

The key factors driving global intravenous immunoglobulin market growth include:
 

  • The rising geriatric population, growing implementation of IVIG procedures, high prevalence of immunodeficiency disorders, and increasing usage of off-label indications, will fuel market growth.
     
  • The growing number of patients with immunodeficiency disease is a major supporting factor for the expansion of IVIG procedures.
     
  • Rising prevalence of primary immune deficiency will accelerate the demand for intravenous immunoglobulin treatments over the forecast period.
     
  • The demand for IVIG treatments for acquired and primary immunodeficiency is on rise, since it is the most effective and the only treatment option available for these disorders.
     
  • Increasing adoption of sedentary lifestyle, including the consumption of unhealthy foods, less physical activity, and high alcohol intake has increased people’s susceptibility to immunodeficiency, which is a positive sign for market growth.
     
  • Increasing prevalence of lifestyle disorders including obesity and antibody deficiency disorders are important driving forces for global intravenous immunoglobulin market.
     

Based on application, the report bifurcates the global intravenous immunoglobulin market into Chronic Inflammatory Demyelinating Polyneuropathy, Hypogammaglobulinemia, Immunodeficiency diseases, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Kawasaki disease, Idiopathic Thrombocytopenic Purpura (ITP), Multifocal motor neuropathy, and Guillain-Barre syndrome.
 

In 2017, Hypogammaglobulinemia was anticipated to be the leading application segment, owing to the increasing occurrences of primary immunodeficiency diseases (PID) globally. The condition is the most common chronic immune defect among patients suffering from lymphoproliferative disorders (LPDs). As per the Centers for Disease Control and Prevention, in 2012, the number of hypogammaglobulinemia cases across the world was around 2 per 100,000 individuals. Additionally, the prevalence of such diseases is projected to rise throughout the forecast period, indicating the high implementation of IVIG therapies, boosting segmental growth in the coming years, cites the report.
 

Request sample copy of this Report@ https://www.marketstudyreport.com/request-a-sample/1695093/
 

The eminent players operating in the competitive landscape of the global intravenous immunoglobin market include Baxter International Inc., Grifols S.A, CSL Ltd., Octapharma AG, LFB group, Kedrion Biopharma Inc., Biotest AG, BDI Pharma Inc., China Biologics Products, Inc., and Bayer Healthcare among others. Profiles of these companies have also been detailed in the report alongside their business overview, product benchmarking, financials, and recent developments. These companies are progressively launching new treatments in an effort to meet evolving patient demands and enhance their position in the business space.


In addition, the report also delivers a comprehensive analysis of the intravenous immunoglobin market drivers, restraints, and opportunities during the projected timeline. A detailed analysis of the market based on application spectrum and regional landscape is also included in the report.